Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS
$14.63
+0.10 (+0.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-2.9M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$195M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.6%
↓Gross Margin
56.6%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+6.7%
FCF CAGR
—
FCF margin
3.9%
FCF / Net income
-0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $112.8M · net income $-10.9M · FCF $4.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $112.8M | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M | $130.5M | $114.6M | $105.6M | $113.4M | $103.4M | $93.0M | $105.6M | $75.1M | $71.4M | $64.8M | $55.6M | $40.1M |
| Net Income | $-10.9M | $-10.9M | $-56.4M | $-82.7M | $-14.9M | $4.1M | $-24.0M | $27.2M | $18.7M | $31.8M | $32.5M | $30.8M | $38.3M | $20.6M | $11.8M | $8.5M | $4.3M | $3.7M |
| EBITDA | $-5.3M | $-5.3M | $3.0M | $15.1M | $18.2M | $9.1M | $-22.2M | $39.2M | $27.7M | $50.0M | $54.3M | $51.9M | $66.2M | $37.4M | $24.2M | $18.0M | $10.9M | $6.9M |
| EPS | -0.76 | -0.76 | -3.83 | -5.64 | -1.02 | 0.28 | -1.69 | 1.89 | 1.27 | 2.11 | 2.15 | 2.01 | 2.51 | 1.39 | 0.82 | 0.62 | 0.32 | 0.32 |
| Gross Margin | 56.6% | 56.6% | 63.4% | 68.3% | 64.3% | 56.1% | 52.9% | 74.9% | 70.4% | — | — | — | — | — | — | — | — | — |
| Operating Margin | -9.8% | -9.8% | -4.3% | 0.7% | 3.2% | 1.8% | -21.7% | 29.9% | 20.6% | 40.3% | 49.0% | 51.8% | 58.2% | 43.4% | 27.6% | 21.6% | 13.6% | 13.9% |
| Net Margin | -9.6% | -9.6% | -47.0% | -68.4% | -13.1% | 2.8% | -18.4% | 23.7% | 17.7% | 28.1% | 31.5% | 33.1% | 36.3% | 27.4% | 16.5% | 13.1% | 7.8% | 9.2% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.18 | 0.18 | 0.17 | 0.13 | 0.11 | — | — | — | — | — | — | — | — | — | 0.07 | 0.10 | 0.13 | — |
| Current Ratio | 4.46 | 4.46 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $4.4M | $4.4M | $-2.9M | $-7.2M | $-3.1M | $3.3M | $11.4M | $34.2M | $30.3M | $31.8M | $10.4M | $30.7M | $38.4M | $24.7M | $9.0M | $8.8M | $5.1M | $-867527.00 |
| Returns | ||||||||||||||||||
| ROE | -7.6% | -7.6% | -36.6% | -38.9% | -5.2% | 1.4% | -8.8% | 9.4% | 7.1% | 12.1% | 14.6% | 14.6% | 21.5% | 15.2% | 10.8% | 8.9% | 5.1% | 4.5% |
| Valuation | ||||||||||||||||||
| EV/EBITDA | — | — | 69.09 | 18.75 | 21.09 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.46 | 1.46 | 1.55 | 1.52 | 1.53 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -5.9% | -5.9% | -0.7% | 6.1% | — | 13.3% | 13.8% | 8.6% | -6.9% | 9.7% | 11.2% | -11.9% | 40.6% | 5.2% | 10.2% | 16.6% | 38.4% | — |
| EPS Growth | 80.2% | 80.2% | 32.1% | -452.9% | — | 116.6% | -189.4% | 48.8% | -39.8% | -1.9% | 7.0% | -19.9% | 80.6% | 69.5% | 32.3% | 93.8% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+31.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.83 → -0.76
Residual
+31.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.